Slide 1: Pemgarda Launch Update
Exhibit 99.2 PEMGARDA LAUNCH UPDATE April 4, 2024 © 2024 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words
Slide 3: Agenda
AGENDA 1. Opening remarks & business updates − Dave Hering, Chief Executive Officer 2. Commercial progress and plans − Jeremy Gowler, Chief Operating & Commercial Officer 3. Financial summary and updates − Bill Duke, Chief Financial Officer 4. Q&A 3
Slide 4: Exciting progress made weeks after receiving EUA for Pemgarda
LESS THAN 2 WEEKS AFTER RECEIVING AN EUA FOR PEMGARDA, EXCITING PROGRESS HAS BEEN MADE • PEMGARDA is now available for order in the U.S. through major distributors • Based on anticipated 2024 net product revenue in the range of $150-200 million and continued optimization of operational spend, compan
Slide 5: Invivyd continues to rapidly execute to plan
INVIVYD CONTINUES TO RAPIDLY EXECUTE TO PLAN Our commercial strategy is built around 3 main phases Product Securing Full Commercial Availability Reimbursement Implementation & Access Deploy national account managers Fully deploy contracted Key Publish WAC in pricing compendia √√ focused on payor eng
Slide 6: We plan to share several launch metrics to provide visibility into our progress
WE PLAN TO SHARE SEVERAL LAUNCH METRICS TO PROVIDE VISIBILITY INTO OUR PROGRESS Anticipated metrics: Patient lives covered by CMS & commercial payors Progress reaching/calling on top 200 institutions identified Number of accounts that have ordered product Number of accounts placing reorders Number o
Slide 7: Financial Summary & Updates
FINANCIAL SUMMARY & UPDATES Insights on anticipated margins: Financial summary: • We expect to begin reporting PEMGARDA net product • Cash and cash equivalents of $200.6M as of revenue and associated COGS in Q2 2024 earnings update Dec 31, 2023 • Notably, in connection with receiving an EUA from the
Slide 8: Invivyd Q&A
INVIVYD Q&A
Slide 9: Invivyd
INVIVYD ! flea) | | | |